Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) saw a significant drop in short interest in December. As of December 31st, there was short interest totalling 2,700,000 shares, a drop of 5.6% from the December 15th total of 2,860,000 shares. Approximately 7.6% of the shares of the company are short sold. Based on an average trading volume of 223,000 shares, the days-to-cover ratio is currently 12.1 days.
Several analysts have commented on AMPH shares. Zacks Investment Research lowered Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, October 24th. BidaskClub lowered Amphastar Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Wednesday, January 8th. ValuEngine raised Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, December 3rd. Finally, TheStreet lowered Amphastar Pharmaceuticals from a “b-” rating to a “c” rating in a report on Thursday, November 7th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $24.05.
In other Amphastar Pharmaceuticals news, General Counsel Jason B. Shandell sold 8,205 shares of the firm’s stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $19.13, for a total value of $156,961.65. Following the sale, the general counsel now directly owns 138,898 shares of the company’s stock, valued at $2,657,118.74. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, General Counsel Jason B. Shandell sold 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $18.44, for a total value of $461,000.00. Following the completion of the sale, the general counsel now directly owns 163,898 shares in the company, valued at $3,022,279.12. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 35,205 shares of company stock valued at $656,467. 30.80% of the stock is owned by company insiders.
AMPH traded down $0.02 during trading on Thursday, hitting $20.01. The company’s stock had a trading volume of 59,462 shares, compared to its average volume of 195,620. The company has a current ratio of 3.11, a quick ratio of 1.84 and a debt-to-equity ratio of 0.13. The business’s fifty day simple moving average is $19.16 and its 200 day simple moving average is $19.96. The firm has a market capitalization of $948.66 million, a price-to-earnings ratio of 95.29 and a beta of 1.16. Amphastar Pharmaceuticals has a twelve month low of $16.71 and a twelve month high of $25.43.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.08 by $0.02. The firm had revenue of $80.14 million for the quarter, compared to analyst estimates of $78.53 million. Amphastar Pharmaceuticals had a return on equity of 5.07% and a net margin of 15.77%. The business’s revenue was up 6.1% on a year-over-year basis. During the same period in the previous year, the company posted $0.12 earnings per share. As a group, equities research analysts forecast that Amphastar Pharmaceuticals will post 0.05 earnings per share for the current fiscal year.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.
Recommended Story: What does the Producer Price Index (PPI) tell investors?
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.